Contrary to an article in the March 11 issue ofBioWorld about CellPro Inc.'s patent dispute withJohns Hopkins University, which indicated thatthe company's Ceprate SC stem cellconcentration system is in early clinical trials, thecompany submitted a pre-marketing approval(PMA) application to FDA for the system lastDecemberAlso, an article in the same issue about AmgenInc.'s collaboration with Amcell Corp. neglectedto say that while the Ceprate SC system'scollection of stem cells from bone marrow wasthe basis for the company's PMA submission,most of CellPro's 40 clinical trials on Ceprate SCfocus on the collection of stem cells fromperipheral blood.031794 Corrections

(c) 1997 American Health Consultants. All rights reserved.